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Immunologic Assessment in Patients 
with Prostatic Carcinoma 
Richard C. Klugo, M D * 
The role of immune mechanisms in the 
development and control of prostatic car-
cinoma appears to be complicated by the 
endocrine response of some tumors. The 
progression of endocrine-independent tu-
mors is more directly related to host-immune 
response. Evaluation of the role of chemo-
therapeutic agents must include their effect 
on the host-immune response. The use of 
BCC in patients with metastatic prostatic 
carcinoma produces no alteration in cell-
mediated immunity but produces local 
tumor necrosis. The use of nonspecific anti-
gens to enhance host-immune response may 
be more effective when used as adjuvant 
therapy in earlier stages of prostatic 
adenocarcinoma. 
* Division of Urology, Department of Surgery 
Address reprint requests to Dr. Klugo at Henry 
Ford Hosp i ta l , 2799 West Grand Boulevard, 
Detroit Ml 48202 
Immunologic evaluation of patients with 
urologic carcinoma has been used to obtain 
a correlation between immune responsive-
ness and tumor progression.^"' This infor-
mation could lead to improved management 
of these patients by avoiding or limiting 
therapy which might depress immune re-
sponse." Alternately or additionally, a non-
specific or tumor-specific antigen might 
enhance the immune response to limit tumor 
extension.^'' 
The presence or absence of cell-mediated 
immunocompetence correlates very closely 
to the disease stage in bladder carc i -
noma.^' '-^ Prel iminary studies of immu-
nocompetence in patients with carcinoma of 
the prostate are conflicting.''" Catalona and 
associates found no correlation between 
lack of immunocompetenceand tumor stage 
with carcinoma of the prostate.' Huus and 
Perskey, alternatively, found a direct cor-
relat ion between DNCB react iv i ty and 
tumor stage.' They suggested that a careful 
evaluation of tumor stage is important to the 
proper assessment of reactivity with car-
cinoma of the prostate. However, when the 
patients receiving endocrine therapy are 
eliminated from Catalona's series, tumor 
progression correlates very closely with im-
mune response. It must be noted that the 
exact role of host-immune response with 
carcinoma of the prostate may be altered 
when hormone dependent tumors are 
present. 
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The cell-mediated response in carcinoma 
of the prostate is altered by what appears to 
be two different mechanisms. Serum factors 
have been shown to produce an impaired 
lymphocyt ic react iv i ty to phytohemag-
glutinin (PHA)."'^"'"'^''^" This may be the 
resultof a blocking antibody, probably pres-
ent in the A2 globulin fraction. A second 
mechanism appears to involve a decrease in 
the absolute lymphocyte count as well as 
abil ity of these lymphocytes to react to PHA 
when incubated with normal serum.'' 
Alteration of immune response may play a 
significant role in the progression of prostatic 
carcinoma. Present modes of therapy have 
shown they may alter lymphocyte response 
and total lymphocytic counts. The ultimate 
role of these responses is not yet fully appar-
ent but is the subject of further investigation. 
Radiation therapy 
Patients in all stages of prostatic car-
cinoma, who had a course of radiation 
therapy within 12 months of lymphocyte 
counts, showed significant depression of 
total and T lymphocyte counts.^' This reduc-
tion was greater in patients with metastatic 
disease. It would appear that recovery of 
lymphocyte counts requires a minimum of 
24 months.^'' During this period of immune 
suppression, metastatic disease may escape 
immune controls. It would seem logical 
during this time to attempt to enhance im-
mune response or to use adjuvant chemo-
therapy or endocrine therapy. 
Chemotherapy 
Agents with antiproliferative properties 
against lymphocytes are being used more 
and it is well to recognize their effect in the 
total management of prostatic carcinoma. 
Cyclophosphamide produces a profound 
leukopenia within 7 to 12 days. It also has the 
potential to induce specific tolerance when 
administered during the inductive phase of 
immune response. Mounting evidence sug-
gests that cyclophosphamide has a preferen-
t ial effect on B lymphocytes. Thus, the 
reduct ion of enhancing ant ibodies by B 
lymphocyte suppression may increase cellu-
lar tumor cytotoxic activity." 
5-Fluoruracil 
This agent exerts its antineoplastic effect 
during the S phase of the cell cycle. In 
therapeutic doses it suppresses delayed hy-
persensitivity and antibody production. It 
would appear that immunosuppression with 
this drug might allow tumor escape and 
progression. The depression of lymphocyte 
levels with this agent is reflected in a moder-
ate T lymphocyte reduction. The most inter-
esting observation is with 5-FU-induced 
tumor remission where T lymphocyte counts 
rebounded to above pretreatment levels."'" 
This may be explained by a reduction of 
tumor bulk and, therefore, serum factors 
which may suppress lymphocyte prolifera-
tion. To evaluate properly the antineoplastic 
agent's capabil ities to control tumor growth, 
it is apparent that concurrent host immune 
monitoring is essential. 
Estrogen therapy 
(Diethyl Stilbesterol 1 mg/d 
Chlorotrianisene 12 mg/d) 
In patients treated with these estrogens 
phytohemagglut in in-st imulated blasto-
genesis was depressed. Despite this finding, 
there was an elevation in the absolute 
lymphocyte and monocyte counts as well as 
improved delayed cutaneous hypersen-
sitivity response to PPD. Examination of 
humoral immune parameters showed an 
increase in the total protein most evident in 
the Alpha 2 globulin. 
Caution must be exerted in interpreting 
the host-immune response during estrogen 
therapy, particularly if significant tumor vol-
ume reduction occurs during this time. It 
would seem that, if the total immune re-
sponse is depressed duringestrogen therapy, 
an approach to combined therapy with im-
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mune st imulat ion or pulse endocr ine 
therapy should be considered. 
Orchiectomy 
Studies, in a small group of patients, of 
lymphocyte populations pre- and post-
orchiectomy produced inconclusive evi-
dence. Improved absolute lymphocyte 
counts were reported in 3 of 5 patients. 
However, indications of tumor volume al-
terations were not noted." It would seem 
that considerable study should be directed to 
Investigation of host-immune response pre-
and post-ore hiectomy. 
BCG-Bacillus Calmette Guerin 
This antigen has been used to produce 
some dramatic responses with melanomas.^" 
Its use with prostatic carcinoma has been 
limited. The modes of administration have 
been oral as well as intralesional. Oral BCG 
failed to produce any improvement in cellu-
lar immune response or tumor regression. 
Intralesional injection produces localized 
tumor necrosis but fails to induce any 
change in cellular immune response.''^^ 
Side effects of intralesional injections oc-
curred with the third and fourth injections 
and consisted of fever. Anaphylactic reac-
tion has been reported with intralesional 
injection. The poor response to BCG in 
patients with advanced prostatic cancer may 
indicate a need for other modes of therapy 
to reduce tumor bulk prior to immu-
notherapy. The need for evaluation of other 
antigens (corynibacterium parvum, KLH)" 
and other sites of introduction (bladder, 
lower extremity) appears indicated in future 
attempts to enhance the immune response. 
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